Lotte Chilsung Beverage (005300) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
1 Apr, 2026Executive summary
Consolidated Q4 2025 sales declined 3.1% year-over-year to 8,943 billion KRW, with operating profit dropping to -120 billion KRW from 92 billion KRW, reflecting a challenging quarter.
Full-year 2025 consolidated sales decreased 1.3% to 39,711 billion KRW, and operating profit fell 9.6% to 1,672 billion KRW.
Net profit for Q4 2025 was -439 billion KRW, a significant decline from -217 billion KRW in Q4 2024.
Financial highlights
Q4 2025 consolidated operating margin dropped to -1.3% from 1.0% in Q4 2024; full-year margin fell to 4.2% from 4.6%.
Beverage segment Q4 sales fell 6.4% year-over-year, with operating profit at -179 billion KRW, down from -80 billion KRW.
Liquor segment Q4 sales declined 7.7% year-over-year, with operating profit at -28 billion KRW, down from 91 billion KRW.
Overseas business Q4 sales grew 3.5% year-over-year, with operating profit up to 102 billion KRW from 95 billion KRW.
Full-year overseas sales rose 4.6% to 10,765 billion KRW, with operating profit up 41.9% to 474 billion KRW.
Outlook and guidance
2026 consolidated sales are projected to rise 3.2% to 41,000 billion KRW, with operating profit expected to increase 19.6% to 2,000 billion KRW.
Beverage segment sales are forecast to grow 3.1%, liquor by 2.3%, and overseas by 4.4% in 2026.
Operating profit margins are expected to improve across all segments in 2026.
Latest events from Lotte Chilsung Beverage
- Q2 sales up 38.1% YoY, but net profit and margins fell as overseas drove growth.005300
Q2 202423 Jun 2026 - Sales and profits fell, but zero-calorie and health products drove segment growth.005300
Q3 202423 Jun 2026 - Q1 2025 revenue and profit declined, with rising debt ratio and segment performance shifts.005300
Q1 202523 Jun 2026 - Profit growth in Q2 2025 driven by overseas and zero-calorie products, with strong full-year outlook.005300
Q2 202523 Jun 2026 - Profits and margins rose in Q3 2025, with overseas and health-focused products driving growth.005300
Q3 202523 Jun 2026 - Q1 2026 delivered sharp profit gains, margin expansion, and robust overseas segment growth.005300
Q1 202622 Jun 2026 - Record sales in 2024 offset by profit decline; 2025 targets strong growth and margin recovery.005300
Q4 20245 Jun 2025